Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PURE BiosciencePURE +0.14% Equity-to-Asset is -3.75 as of Apr. 2026. The stock has 5 warning signs investors should review. Among 2,013 Consumer Packaged Goods companies, PURE Bioscience ranks worse than 99.01% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PURE Bioscience's Total Stockholders Equity for the quarter that ended in Apr. 2026 was $-5.84 Mil. PURE Bioscience's Total Assets for the quarter that ended in Apr. 2026 was $1.56 Mil.
Therefore, PURE Bioscience's Equity to Asset Ratio for the quarter that ended in Apr. 2026 was -3.75.
The historical rank and industry rank for PURE Bioscience's Equity-to-Asset or its related term are showing as below:
PURE'
s Equity-to-Asset Range Over the Past 10 Years
Min: -7.96 Med: 0.63 Max: 0.88
Current: -3.75
During the past 13 years, the highest Equity to Asset Ratio of PURE Bioscience was 0.88. The lowest was -7.96. And the median was 0.63.
PURE's Equity-to-Asset is ranked worse than 99.01% of 2013
companies
in the Consumer Packaged Goods industry
Industry Median: 0.55
vs PURE: -3.75
PURE Bioscience (OTCPK:PURE) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
PURE Bioscience Equity-to-Asset Related Terms
PURE Bioscience Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for PURE Bioscience's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE vs DQWS, RAY, TANH: Equity-to-Asset Comparison
For the Household & Personal Products subindustry, PURE Bioscience's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PURE Bioscience Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where PURE Bioscience's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
PURE Bioscience's Equity to Asset Ratio for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE Bioscience (PURE) has a Equity-to-Asset of -3.75 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PURE Bioscience and its competitors. According to the industry distribution chart, PURE Bioscience ranks #1993 out of 2013 companies in the Consumer Packaged Goods industry, placing it in the top 99%.
Is PURE Bioscience's Equity-to-Asset too high?
PURE Bioscience's current Equity-to-Asset is -3.75. Based on the distribution chart, PURE Bioscience ranks #1993 out of 2013 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers.
How does PURE Bioscience's Equity-to-Asset compare to DQWS and RAY?
According to the Consumer Packaged Goods industry distribution chart, PURE Bioscience ranks #1993 out of 2013 companies for Equity-to-Asset. This places PURE Bioscience in the lower half of its industry. The industry median Equity-to-Asset is 0.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 2,013 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PURE Bioscience and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PURE Bioscience's current Equity-to-Asset is -3.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PURE Bioscience stock overvalued right now?
Based on GuruFocus' analysis, PURE Bioscience (PURE) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 30% below its estimated fair value. The current Equity-to-Asset is -3.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For PURE Bioscience (PURE), the current Equity-to-Asset is -3.75 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, and products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The company generates revenue from the sale of its antimicrobial products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PURE has been successfully added to your 
